

# Å<sup>1/2</sup>eljko Reiner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4756874/publications.pdf>

Version: 2024-02-01

215  
papers

65,704  
citations

12330

69  
h-index

1715

213  
g-index

223  
all docs

223  
docs citations

223  
times ranked

52369  
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.2	5,681
2	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	2.2	5,247
3	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.2	5,233
4	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,034
5	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
6	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	2.2	3,465
7	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	2.2	3,144
8	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	2.2	2,767
9	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
10	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	2.2	2,393
11	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0:78431478BT /Over	2.2	2,331
12	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
13	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758
14	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2851-2906.	2.2	1,394
15	Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal, 2010, 31, 2844-2853.	2.2	1,392
16	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.8	1,189
17	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 2011, 32, 1345-1361.	2.2	993
18	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq0 0 0:78431478BT /Over	2.2	993

#	ARTICLE	IF	CITATIONS
19	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648.	1.8	772
20	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 3-46.	0.8	561
21	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
22	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.8	414
23	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 2008, 102, 1K-34K.	1.6	371
24	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.8 BT / Overlock 10 T	0.8	414
25	European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis, 2007, 194, 1-45.	0.8	292
26	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. European Heart Journal, 2014, 35, 960-968.	2.2	270
27	Hypertriglyceridaemia and risk of coronary artery disease. Nature Reviews Cardiology, 2017, 14, 401-411.	13.7	257
28	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	5.8	238
29	Lysosomal acid lipase deficiency â€“ An under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis, 2014, 235, 21-30.	0.8	232
30	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research, 2008, 5, 319-335.	2.0	227
31	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis, 2019, 285, 135-146.	0.8	227
32	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	1.7	224
33	Statins and the COVID-19 main protease: in silico evidence on direct interaction. Archives of Medical Science, 2020, 16, 490-496.	0.9	218
34	The Role of Nutraceuticals in StatinÂntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	2.8	216
35	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.9	206
36	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. Circulation, 2014, 129, 999-1008.	1.6	197

#	ARTICLE	IF	CITATIONS
37	EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 530-540.	2.8	193
38	Resistance and intolerance to statins. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1057-1066.	2.6	183
39	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 1-44.	0.8	180
40	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries â€“ Findings from the EUROASPIRE IV survey. Atherosclerosis, 2016, 246, 243-250.	0.8	173
41	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
42	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complementary Therapies in Medicine, 2017, 33, 1-5.	2.7	160
43	Statins in the primary prevention of cardiovascular disease. Nature Reviews Cardiology, 2013, 10, 453-464.	13.7	156
44	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. European Journal of Preventive Cardiology, 2016, 23, 2007-2018.	1.8	153
45	The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. Frontiers in Pharmacology, 2020, 11, 1300.	3.5	152
46	Prevalence of statin intolerance: a meta-analysis. European Heart Journal, 2022, 43, 3213-3223.	2.2	151
47	Relation of Atherosclerotic Changes in Retinal Arteries to the Extent of Coronary Artery Disease. American Journal of Cardiology, 2005, 96, 1107-1109.	1.6	146
48	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis, 2015, 241, 169-175.	0.8	133
49	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€. Atherosclerosis, 2018, 275, 265-272.	0.8	131
50	The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Food and Function, 2019, 10, 6042-6051.	4.6	121
51	Physiciansâ€™ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey. Atherosclerosis, 2010, 213, 598-603.	0.8	118
52	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 799-807.	2.6	111
53	Adverse Effects of Statins - Myths and Reality. Current Pharmaceutical Design, 2015, 21, 1220-1226.	1.9	107
54	Population-level changes to promote cardiovascular health. European Journal of Preventive Cardiology, 2013, 20, 409-421.	1.8	106

#	ARTICLE	IF	CITATIONS
55	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
56	Title page. American Journal of Cardiology, 2008, 102, i.	1.6	103
57	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2015, 14, 133.	6.8	101
58	Management of patients with familial hypercholesterolaemia. Nature Reviews Cardiology, 2015, 12, 565-575.	13.7	101
59	Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. Current Cardiology Reports, 2012, 14, 709-720.	2.9	93
60	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
61	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2019, 143, 1-16.	7.1	90
62	Blood pressure control and knowledge of target blood pressure in coronary patients across Europe. Journal of Hypertension, 2011, 29, 1641-1648.	0.5	89
63	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism: Clinical and Experimental, 2016, 65, 1664-1678.	3.4	85
64	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation, 2019, 140, 2054-2062.	1.6	83
65	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. European Journal of Preventive Cardiology, 2021, 28, 370-379.	1.8	83
66	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.8	83
67	Combined therapy in the treatment of dyslipidemia. Fundamental and Clinical Pharmacology, 2010, 24, 19-28.	1.9	81
68	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. European Journal of Preventive Cardiology, 2015, 22, 1354-1362.	1.8	81
69	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. International Journal of Cardiology, 2016, 209, 284-290.	1.7	77
70	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal Supplements, 2016, 18, C2-C12.	0.1	71
71	Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. Pharmacological Research, 2017, 122, 53-65.	7.1	67
72	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. Atherosclerosis, 2013, 231, 300-307.	0.8	66

#	ARTICLE	IF	CITATIONS
73	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate“statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
74	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacological Research, 2020, 158, 104891.	7.1	62
75	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research, 2021, 166, 105499.	7.1	62
76	Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. European Heart Journal, 2012, 33, 2865-2872.	2.2	59
77	Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey. Preventive Medicine, 2010, 51, 494-496.	3.4	58
78	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 212, 160-168.	1.7	51
79	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Drugs, 2016, 76, 947-956.	10.9	46
80	Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. European Heart Journal, 2014, 35, 590-598.	2.2	44
81	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. European Journal of Preventive Cardiology, 2017, 24, 1383-1401.	1.8	43
82	Effects of Rice Policosanol on Serum Lipoproteins, Homocysteine, Fibrinogen and C-Reactive Protein in Hypercholesterolaemic Patients. Clinical Drug Investigation, 2005, 25, 701-707.	2.2	42
83	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. European Journal of Preventive Cardiology, 2016, 23, 1202-1210.	1.8	42
84	Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators of Inflammation, 2022, 2022, 1-20.	3.0	42
85	Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases. Journal of Clinical Medicine, 2022, 11, 1313.	2.4	40
86	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. Cancer Cell International, 2020, 20, 560.	4.1	39
87	Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19. International Journal for Vitamin and Nutrition Research, 2022, 92, 49-66.	1.5	39
88	PCSK9 inhibitors “ past, present and future. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1517-1521.	3.3	37
89	Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment. Plant Foods for Human Nutrition, 2020, 75, 307-315.	3.2	37
90	Management of overweight and obese patients with coronary heart disease across Europe. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 447-454.	2.8	36

#	ARTICLE	IF	CITATIONS
91	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , 2018, 50, 565-575.	3.8	36
92	Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 646-654.	2.8	35
93	Step-by-step diagnosis and management of the nocebo/drug effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	7.3	35
94	The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2020, 34, 239-253.	5.8	34
95	The perception and knowledge of cardiovascular risk factors among medical students. <i>Croatian Medical Journal</i> , 2012, 53, 278-284.	0.7	33
96	Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1212-1219.	1.8	33
97	Educational level and risk profile and risk control in patients with coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 881-890.	1.8	33
98	Effects of resistant starch on glycemic control, serum lipoproteins and systemic inflammation in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 3172-3184.	10.3	33
99	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	1.8	33
100	Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 163-174.	1.9	32
101	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 162-171.	3.4	32
102	PCSK9 inhibitors in clinical practice: Expectations and reality. <i>Atherosclerosis</i> , 2018, 270, 187-188.	0.8	32
103	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Española De Cardiología</i> , 2012, 65, 938.e1-938.e59.	1.2	31
104	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
105	The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Lipids in Health and Disease</i> , 2020, 19, 112.	3.0	31
106	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	4.1	31
107	The burden of hyperlipidaemia and diabetes in cardiovascular diseases. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 1-3.	1.9	30
108	Prevalence and types of persistent dyslipidemia in patients treated with statins. <i>Croatian Medical Journal</i> , 2013, 54, 339-345.	0.7	30



#	ARTICLE	IF	CITATIONS
109	Medicinal plants and bioactive natural compounds as inhibitors of <sc>HMGâ€CoA</sc> reductase: A literature review. BioFactors, 2020, 46, 906-926.	5.4	30
110	Fetal toxicity associated with statins: A systematic review and meta-analysis. Atherosclerosis, 2021, 327, 59-67.	0.8	30
111	Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. Cancer Cell International, 2021, 21, 388.	4.1	30
112	Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9â€A Narrative Review. Cardiovascular Therapeutics, 2022, 2022, 1-6.	2.5	30
113	Cardiovascular disease (CVD) risk factors in older adults â€ Perception and reality. Archives of Gerontology and Geriatrics, 2015, 61, 88-92.	3.0	29
114	The effects of L-carnitine supplementation on indicators of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes and Metabolic Disorders, 2020, 19, 1879-1894.	1.9	29
115	Primary Prevention of Cardiovascular Disease with Statins in the Elderly. Current Atherosclerosis Reports, 2014, 16, 420.	4.8	28
116	The effects of <i>n</i>-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial. British Journal of Nutrition, 2020, 123, 792-799.	2.3	27
117	The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. Complementary Therapies in Medicine, 2020, 48, 102250.	2.7	27
118	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. European Journal of Preventive Cardiology, 2022, 29, 328-339.	1.8	27
119	Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. Frontiers in Cardiovascular Medicine, 2022, 9, 820260.	2.4	27
120	Improvement of endothelial function by pitavastatin: a meta-analysis. Expert Opinion on Pharmacotherapy, 2018, 19, 279-286.	1.8	26
121	PCSK9 and infection: A potentially useful or dangerous association?. Journal of Cellular Physiology, 2018, 233, 2920-2927.	4.1	26
122	The year in cardiology 2018: prevention. European Heart Journal, 2019, 40, 336-344.	2.2	26
123	Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia. Circulation Research, 2014, 114, 233-235.	4.5	25
124	The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: A systematic review and metaâ€analysis of randomized controlled trials. Phytotherapy Research, 2019, 33, 2609-2621.	5.8	25
125	Effects of statins on preeclampsia: A systematic review. Pregnancy Hypertension, 2021, 23, 123-130.	1.4	25
126	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. International Journal of Cardiology, 2018, 272, 20-25.	1.7	24



#	ARTICLE	IF	CITATIONS
127	The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis. <i>Biomolecules</i> , 2019, 9, 416.	4.0	24
128	A review of gene- and cell-based therapies for familial hypercholesterolemia. <i>Pharmacological Research</i> , 2019, 143, 119-132.	7.1	24
129	Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. <i>Croatian Medical Journal</i> , 2011, 52, 566-575.	0.7	23
130	The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu. <i>Journal of Clinical Medicine</i> , 2019, 8, 1413.	2.4	23
131	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1630-1636.	1.8	23
132	Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 197-208.	2.6	22
133	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	5.7	22
134	The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2020, 38, 43-49.	1.2	21
135	Macrophage: A Key Therapeutic Target in Atherosclerosis?. <i>Current Pharmaceutical Design</i> , 2019, 25, 3165-3174.	1.9	21
136	Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 84-91.	1.8	20
137	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1618-1627.	1.8	19
138	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 801-809.	1.5	19
139	Postmarketing nutravigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021, 17, 856-863.	0.9	19
140	Quercetin as a Novel Therapeutic Approach for Lymphoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	4.0	19
141	Diabetic dyslipidemia or "diabetes lipidus"? <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 341-348.	1.5	18
142	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2019, 15, 1365-1374.	0.9	18
143	Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 575877.	3.5	18
144	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. <i>Atherosclerosis</i> , 2022, 348, 25-35.	0.8	18

#	ARTICLE	IF	CITATIONS
145	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
146	A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels. Current Medicinal Chemistry, 2016, 23, 4490-4503.	2.4	17
147	Unterschiede in den Risikofaktoren für koronare Herzkrankheit bei kroatischen Patienten von kontinentalen und mediterranen Regionen. Wiener Klinische Wochenschrift, 2008, 120, 684-692.	1.9	16
148	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
149	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal, 2018, 48, 1097.	1.9	15
150	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. Current Atherosclerosis Reports, 2019, 21, 14.	4.8	15
151	Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatria Danubina, 2007, 19, 270-81.	0.4	15
152	New Therapeutic Approaches in Treatment of Dyslipidaemia – A Narrative Review. Pharmaceuticals, 2022, 15, 839.	3.8	15
153	Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?. Cardiology, 2015, 131, 225-227.	1.4	14
154	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2018, 8, e021508.	1.9	14
155	Novel Experimental Agents for the Treatment of Hypercholesterolemia. Journal of Experimental Pharmacology, 2021, Volume 13, 91-100.	3.2	14
156	Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins. Croatian Medical Journal, 2004, 45, 333-7.	0.7	14
157	New ESC/EAS Guidelines for the management of dyslipidaemias – any controversies behind the consensus?. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 724-727.	2.8	13
158	A comparison of European and US guidelines for familial hypercholesterolaemia. Current Opinion in Lipidology, 2015, 26, 215-220.	2.7	13
159	Treatment of children with homozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2018, 25, 1095-1097.	1.8	13
160	Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. Reviews of Physiology, Biochemistry and Pharmacology, 2020, 177, 25-52.	1.6	13
161	A systematic review and meta-analysis: The effects of probiotic supplementation on metabolic profile in patients with neurological disorders. Complementary Therapies in Medicine, 2020, 53, 102507.	2.7	13
162	Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. Croatian Medical Journal, 2005, 46, 984-9.	0.7	13

#	ARTICLE	IF	CITATIONS
163	Mutation detection in Croatian patients with Familial Hypercholesterolemia. <i>Annals of Human Genetics</i> , 2013, 77, 22-30.	0.8	12
164	Resveratrol and cardiac fibrosis prevention and treatment. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	1.6	12
165	Impact of Bariatric Surgery on Pulse Wave Velocity as a Measure of Arterial Stiffness: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2021, 31, 4461-4469.	2.1	12
166	Impact of Intravenous Trehalose Administration in Patients with Niemannâ€Pick Disease Types A and B. <i>Journal of Clinical Medicine</i> , 2022, 11, 247.	2.4	12
167	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	4.0	12
168	Clinical Study on the Effect of Simvastatin on Paraoxonase Activity. <i>Arzneimittelforschung</i> , 2007, 57, 647-653.	0.4	11
169	Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. <i>Angiology</i> , 2020, 71, 105-107.	1.8	11
170	The role of statins in lung cancer. <i>Archives of Medical Science</i> , 2021, 18, 141-152.	0.9	11
171	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	3.0	11
172	The effects of catechin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 2369-2378.	10.3	10
173	Statin therapy and sex hormones. <i>European Journal of Pharmacology</i> , 2021, 890, 173745.	3.5	10
174	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. <i>Journal of Clinical Medicine</i> , 2021, 10, 4930.	2.4	10
175	Guidelines, position papers and critical reviews: differences and similarities. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 3-5.	1.8	9
176	Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units. <i>Journal of Clinical Medicine</i> , 2019, 8, 1742.	2.4	9
177	The effects of omega-3 fatty acids supplementation on metabolic status in pregnant women: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1685-1699.	1.9	9
178	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. <i>International Journal of Cardiology</i> , 2021, 322, 227-232.	1.7	9
179	Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 24.	1.6	8
180	The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , 2019, 25, 3266-3281.	1.9	8

#	ARTICLE	IF	CITATIONS
181	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. Journal of Hypertension, 2019, 37, 2015-2023.	0.5	7
182	Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?. Critical Reviews in Food Science and Nutrition, 2021, 61, 325-336.	10.3	7
183	Effects of Statins on Renin-Angiotensin System. Journal of Cardiovascular Development and Disease, 2021, 8, 80.	1.6	7
184	The importance of smoking cessation in patients with coronary heart disease. International Journal of Cardiology, 2018, 258, 26-27.	1.7	6
185	Can we further optimize statin therapy to increase tolerability?. Expert Opinion on Drug Discovery, 2019, 14, 843-847.	5.0	6
186	Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: A meta-analysis of randomized clinical trials. Clinical Nutrition ESPEN, 2020, 37, 24-33.	1.2	6
187	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. Current Medicinal Chemistry, 2021, 28, 6066-6081.	2.4	6
188	The effects of L-carnitine supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. EXCLI Journal, 2019, 18, 631-643.	0.7	6
189	Treatment of children with heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2020, 304, 177-178.	1.7	5
190	Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102381.	2.0	5
191	The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 682352.	2.4	5
192	Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity. Arzneimittelforschung, 2005, 55, 271-275.	0.4	4
193	Statins for primary prevention: problems with cardiovascular-risk estimation?. Nature Reviews Cardiology, 2013, 10, 547-547.	13.7	4
194	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	1.0	4
195	The association between lipid-lowering drugs and circulating concentration of PCSK9. European Journal of Preventive Cardiology, 2019, 26, 928-929.	1.8	4
196	Why might visit-to-visit variability of lipoproteins have an effect on cardiovascular events?. Atherosclerosis, 2020, 312, 99-100.	0.8	4
197	In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). Chemico-Biological Interactions, 2021, 345, 109528.	4.0	4
198	Similarities and differences between European and United States guidelines for the management of dyslipidaemias. Kardiologia Polska, 2015, 73, 471-477.	0.6	4

#	ARTICLE	IF	CITATIONS
199	Rice policosanol does not have any effects on blood coagulation factors in hypercholesterolemic patients. Collegium Antropologicum, 2007, 31, 1061-4.	0.2	4
200	Polypill is not a "vaccine-like" solution for primary cardiovascular disease prevention in all parts of the world. Journal of Epidemiology and Community Health, 2013, 67, 981-982.	3.7	3
201	Oxidative stress mediated cytogenotoxicological effects of phytol in wistar albino rats. Advances in Traditional Medicine, 2023, 23, 273-290.	2.0	3
202	Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 1018-1028.	1.2	3
203	Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. Clinical Lipidology, 2010, 5, 325-328.	0.4	2
204	Guidelines on CVD prevention: confusing or complementary?. European Journal of Preventive Cardiology, 2013, 20, 6-8.	1.8	2
205	Practical guidelines for diagnosing arterial hypertension of the Croatian Society of Hypertension of Croatian Medical Association and the Working Group on Hypertension of the Croatian Cardiac Society. Cardiologia Croatica, 2017, 12, 413-451.	0.0	2
206	Statins in heart failure " A failure?. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 397-401.	2.6	1
207	The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair. Heart Failure Reviews, 2020, , 1.	3.9	1
208	At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products. Journal of Medical Economics, 2020, 23, 1193-1195.	2.1	1
209	Differential Expression of miRNA-223 in Coronary In-Stent Restenosis. Journal of Clinical Medicine, 2022, 11, 849.	2.4	1
210	A pilot Croatian survey of risk factor (CRO-SURF) management in patients with cardiovascular disease. Collegium Antropologicum, 2012, 36, 369-73.	0.2	1
211	Is there any association between plasma lipid profile and severity of COVID-19?. Clinical Nutrition ESPEN, 2022, , .	1.2	1
212	Statistical vs clinical significance: A matter of debate for orlistat treatment. Pharmacological Research, 2017, 124, 158-159.	7.1	0
213	Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach. Journal of the Endocrine Society, 2021, 5, A311-A311.	0.2	0
214	The Effects of N-acetylcysteine on Inflammatory Markers and Homocysteine: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Pharmaceutical Sciences, 2020, 26, 214-224.	0.2	0
215	Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome " A case report. Transfusion and Apheresis Science, 2021, , 103346.	1.0	0